N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom.
+ 1 more risk
Excellent balance sheet with weak fundamentals.
Share Price & News
How has N4 Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: N4P's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: N4P underperformed the UK Pharmaceuticals industry which returned 15.3% over the past year.
Return vs Market: N4P underperformed the UK Market which returned -15.7% over the past year.
Price Volatility Vs. Market
How volatile is N4 Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs N4 Pharma Plc's (LON:N4P) CEO Paid At A Competitive Rate?
5 months ago | Simply Wall StThose Who Purchased N4 Pharma (LON:N4P) Shares A Year Ago Have A 71% Loss To Show For It
7 months ago | Simply Wall StHere's Why We're A Bit Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Is N4 Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate N4P's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate N4P's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: N4P is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: N4P is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate N4P's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: N4P is overvalued based on its PB Ratio (4.4x) compared to the GB Pharmaceuticals industry average (4.2x).
How is N4 Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if N4P's forecast earnings growth is above the savings rate (1.2%).
Earnings vs Market: Insufficient data to determine if N4P's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: N4P is forecast to have no revenue next year.
High Growth Revenue: N4P is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if N4P's Return on Equity is forecast to be high in 3 years time
How has N4 Pharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: N4P is currently unprofitable.
Growing Profit Margin: N4P is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if N4P's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare N4P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: N4P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.3%).
Return on Equity
High ROE: N4P has a negative Return on Equity (-88.76%), as it is currently unprofitable.
How is N4 Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: N4P's short term assets (£1.1M) exceed its short term liabilities (£77.7K).
Long Term Liabilities: N4P has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: N4P's debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if N4P's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: N4P has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: N4P is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.
What is N4 Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate N4P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate N4P's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if N4P's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if N4P's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of N4P's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nigel Theobald (56yo)
Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Pharmaceutic ...
CEO Compensation Analysis
Compensation vs Market: Nigel's total compensation ($USD86.67K) is below average for companies of similar size in the UK market ($USD348.99K).
Compensation vs Earnings: Nigel's compensation has been consistent with company performance over the past year.
|Part-Time Executive Director & Technical Director||3.17yrs||UK£62.79k||no data|
|Head of CMC Development||0.42yr||no data||no data|
|Consultant||1.5yrs||no data||no data|
Experienced Management: N4P's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Part-Time Executive Director & Technical Director||3.17yrs||UK£62.79k||no data|
|Independent Non-Executive Chairman||1.17yrs||UK£14.67k||no data|
|Independent Non-Executive Director||no data||UK£24.00k||0.094% £6.1k|
|Independent Non-Executive Director||1.17yrs||UK£14.92k||no data|
Experienced Board: N4P's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 50%.
N4 Pharma Plc's company bio, employee growth, exchange listings and data sources
- Name: N4 Pharma Plc
- Ticker: N4P
- Exchange: AIM
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£6.544m
- Shares outstanding: 152.19m
- Website: https://www.n4pharma.com
Number of Employees
- N4 Pharma Plc
- 60 Gracechurch Street
- 6th Floor
- Greater London
- EC3V 0HR
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|N4P||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||May 2017|
N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system; and Nanomerics Limited to produce and test two candidate formulations using the Nuvec delivery system. N4 Pharma Plc is based in London, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/01 21:05|
|End of Day Share Price||2020/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.